Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Dtsch Dermatol Ges. 2013 Apr;11(4):338-47. doi: 10.1111/ddg.12012. Epub 2013 Jan 2.

Treatment of advanced cutaneous T-cell lymphomas with non-pegylated liposomal doxorubicin--consensus of the lymphoma group of the Working Group Dermatologic Oncology.

Author information

  • 1Department of Dermatlogy, Helios Clinic Krefeld, Lutherplatz 40, Krefeld, Germany. chalid.assaf@helios-kliniken.de

Abstract

BACKGROUND:

Systemic treatment with pegylated liposomal doxorubicin is an established second-line treatment of advanced cutaneous T-cell lymphoma. Pegylated liposomal doxorubicin (PLD) is currently unavailable, therefore, clinical studies investigating the efficacy of non-pegylated liposomal formula (NPLD) have been analyzed.

METHODS:

Since clinical trials comparing PLD and NPLD in CTCL do not exist, the clinical use of NPLD including safety and efficiency profile in other types of non-Hodgkin lymphoma were analyzed.

RESULTS:

Clinical trials show a comparable efficacy of NPLD and PLD in non-Hodgkin lymphoma. The dosage of NPLD used in the treatment of systemic lymphoma within polychemotherapy regimens was 50 mg/m2 every three weeks. Overall response was 75-95%, including a complete remission rate of 65-80% and 2- and 3-year overall survival rates of 55-75%. These data indicate that the non-pegylated formula of doxorubicin has a similar antitumor effect as the pegylated one but shows reduced cardiotoxicity. The palmoplantar erythrodysesthesia frequently observed in PLD has not been observed with the use of the NPLD.

CONCLUSIONS:

The clinical use of NPLD in the treatment of CTCL is reasonable. In analogy to the clinical trials of NPLD in non-Hodgkin lymphoma a dosage of 50 mg/m(2) every three weeks is recommended for the treatment of CTCL.

© The Authors • Journal compilation © Blackwell Verlag GmbH, Berlin.

PMID:
23279629
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Blackwell Publishing
    Loading ...
    Write to the Help Desk